Trial · NCT05451940
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 13 of 13
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage of Participants With Hemoglobin (Hb) Response | Baseline to 12 weeks | Hb response is defined as a Hb increase of ≥ 1.0 g/dL at 12 weeks compared to baseline |
| Secondary | Change in Number of Blood Transfusions Per Year | Baseline to 12 weeks | Annualized number of units of simple red blood cell transfusions received in the 12 months before treatment initiation, compared to during the treatment period |
| Other | Changes in Tricuspid Valve Regurgitant Jet Velocity as Assessed by Echocardiography | Baseline to 12 weeks; Baseline to 24 weeks | Changes in tricuspid valve regurgitant jet velocity |
| Other | Changes in Cardiac Index as Assessed by Echocardiography | Baseline to 12 weeks; Baseline to 24 weeks | Changes in cardiac index |
| Other | Changes in Left Ventricular End-diastolic Volume as Assessed by Echocardiography | Baseline to 12 weeks; Baseline to 24 weeks | Changes in left ventricular end-diastolic volume |
| Other | Changes in Exercise Capacity as Assessed by 6-minute Walk Test With Modified Borg Dyspnea Scale | Baseline to 12 weeks; Baseline to 24 weeks | Changes in 6-minute walk distance and Modified Borg Dyspnea scale (severity of dyspnea during the 6-minute walk test will be measured on a 10-point scale with 0=nothing at all and 10= maximum severity of breathlessness) |
| Other | Changes in Hemoglobin (Hb) | Baseline to 12 weeks | Mean change in Hb at 12 weeks compared to baseline |
| Other | Changes in Absolute Reticulocyte Count | Baseline to 12 weeks; Baseline to 24 weeks | Changes in absolute reticulocyte count |
| Other | Changes in Lactate Dehydrogenase | Baseline to 12 weeks; Baseline to 24 weeks | Changes in lactate dehydrogenase |
| Other | Changes in Renal Function | Baseline to 12 weeks; Baseline to 24 weeks | Changes in serum creatinine (and associated eGFR) |
| Other | Changes in Urine Albumin-to-creatinine Ratio | Baseline to 12 weeks; Baseline to 24 weeks | Changes in urine albumin-to-creatinine ratio |
| Other | Changes in Total and Indirect Bilirubin | Baseline to 12 weeks; Baseline to 24 weeks | Changes in total and indirect bilirubin |
| Other | Changes in Ferritin | Baseline to 12 weeks; Baseline to 24 weeks | Changes in ferritin |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05451940/registered